Skip to main content

Table 1 Characteristics of MCAD patients

From: Prostaglandin D2-supplemented “functional eicosanoid testing and typing” assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study

MCAS

SM

No.

Sex

Age

Tryptase* [μg/L]

KIT

Medication

No.

Sex

Age

Tryptase [μg/L]

KIT

Medication

1

f

30

2.0

neg.

no

1

f

39

4.6

pos.

yes

2

f

36

3.3

neg.

no

2

f

44

3.3

pos.

yes

3

f

36

9.4

neg.

no

3

f

46

10.5

pos.

yes

4

f

45

3.4

neg.

no

4

f

53

27.0

pos.

yes

5

f

46

11.3

neg.

yes

5

f

55

4.9

pos.

yes

6

f

46

3.0

neg.

no

6

f

70

>200

pos.

yes

7

f

57

3.9

neg.

yes

7

m

44

24.7

pos.

yes

8

f

59

4.4

neg.

yes

8

m

51

>25

pos.

yes

9

f

61

3.6

neg.

no

9

m

52

40.7

pos.

yes

10

f

71

5.7

neg.

no

10

m

69

10.1

pos.

yes

11

m

20

8.1

neg.

no

      

12

m

38

n.d.

neg.

no

      

Mean

 

45.4

   

Mean

 

52.3

   

Median

 

45.5

   

Median

 

51.5

   

Range

 

[20–71]

[2.0-11.3]

Range

 

[39–70]

[3.3- > 200]

  1. f: female; m: male; n.d.: not determined; neg.: KITD816V negative; pos.: KITD816V positive; no: no MCAD-specific medication; yes: MCAD-specific medication (for details see Additional file 1); *ImmunoCAP® Tryptase assay, normal range: < 11.4 μg/L.